Request Samples

Request a Rep

Speaker Programs

Request Samples

Request a Rep

Speaker Programs

GET SAMPLES AND SUPPORT

Get patients started with samples of UBRELVY

Get patients started with samples of UBRELVY

Order samples

Learn more about UBRELVY at upcoming speaker programs

Learn more about UBRELVY at upcoming speaker programs

Register now

DOWNLOAD RESOURCES TO SUPPORT YOUR PATIENTS

U-Concierge for your patients

U-CONCIERGE for your patients

U-CONCIERGE, administered by ASPN Pharmacies, helps enable access to UBRELVY for eligible patients.

Download

UBRELVY Prescription Form

Make it even easier to prescribe UBRELVY. This template will save you time when writing a prescription.

Download

Dosing Card

UBRELVY is available in two strengths.¹Learn more about dosing considerations and how to prescribe.

Download

Dosing information

Access Support Leave-Behind

Access Support Leave Behind

UBRELVY offers a savings program for eligible patients and services to aid along the way. Find helpful information on how to get patients covered.

Download

Download sample templates to support your office

Sample Appeals Letter ›

Letter of Medical Necessity Sample Letter ›

Formulary Exception Letter ›

Tiered Exception Sample Letter ›

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Drug Interactions: UBRELVY is contraindicated with concomitant use of strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin).

Hypersensitivity Reactions: UBRELVY is contraindicated in patients with a history of serious hypersensitivity to ubrogepant or any ingredient of the product. Cases, including anaphylaxis, dyspnea, facial or throat edema, rash, urticaria, and pruritus, have been reported. Hypersensitivity reactions can occur minutes, hours, or days after administration. Most reactions were not serious, and some led to discontinuation. If a serious or severe reaction occurs, discontinue UBRELVY and institute appropriate therapy.

ADVERSE REACTIONS

The most common adverse reactions were nausea (4% vs 2% placebo) and somnolence (3% vs 1% placebo).

DRUG INTERACTIONS

Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure.
Dose modifications are recommended when using the following:
- Moderate or weak CYP3A4 inhibitors and inducers
- BCRP and/or P-gp only inhibitors

DOSAGE AND ADMINISTRATION

The recommended dose is 50 mg or 100 mg taken orally, as needed.
If needed, a second dose may be administered at least 2 hours after the initial dose.
The maximum dose in a 24-hour period is 200 mg. The safety of treating more than 8 migraines in a 30-day period has not been established.
Severe hepatic or severe renal impairment: Recommended dose is 50 mg; if needed, a second 50 mg dose may be taken at least 2 hours after the initial dose.
Avoid use in patients with end-stage renal disease.

INDICATION

UBRELVY^® (ubrogepant) is indicated for the acute treatment of migraine with or without aura in adults. UBRELVY is not indicated for the preventive treatment of migraine.

Please see full Prescribing Information.

US-UBR-230117

Reference: 1. UBRELVY. Package insert. AbbVie Inc; 2023.

IMPORTANT SAFETY INFORMATION

Contraindications

Drug Interactions: UBRELVY is contraindicated with concomitant use of strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin).

IMPORTANT SAFETY INFORMATION

Contraindications

Drug Interactions: UBRELVY is contraindicated with concomitant use of strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin).

IMPORTANT SAFETY INFORMATION

Contraindications

Drug Interactions: UBRELVY is contraindicated with concomitant use of strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin).

IMPORTANT SAFETY INFORMATION

Contraindications

Drug Interactions: UBRELVY is contraindicated with concomitant use of strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin).

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Drug Interactions: UBRELVY is contraindicated with concomitant use of strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin).

Hypersensitivity Reactions: UBRELVY is contraindicated in patients with a history of serious hypersensitivity to ubrogepant or any ingredient of the product. Cases, including anaphylaxis, dyspnea, facial or throat edema, rash, urticaria, and pruritus, have been reported. Hypersensitivity reactions can occur minutes, hours, or days after administration. Most reactions were not serious, and some led to discontinuation. If a serious or severe reaction occurs, discontinue UBRELVY and institute appropriate therapy.

ADVERSE REACTIONS

The most common adverse reactions were nausea (4% vs 2% placebo) and somnolence (3% vs 1% placebo).

DRUG INTERACTIONS

Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure.
Dose modifications are recommended when using the following:
- Moderate or weak CYP3A4 inhibitors and inducers
- BCRP and/or P-gp only inhibitors

DOSAGE AND ADMINISTRATION

The recommended dose is 50 mg or 100 mg taken orally, as needed.
If needed, a second dose may be administered at least 2 hours after the initial dose.
The maximum dose in a 24-hour period is 200 mg. The safety of treating more than 8 migraines in a 30-day period has not been established.
Severe hepatic or severe renal impairment: Recommended dose is 50 mg; if needed, a second 50 mg dose may be taken at least 2 hours after the initial dose.
Avoid use in patients with end-stage renal disease.

INDICATION

UBRELVY^® (ubrogepant) is indicated for the acute treatment of migraine with or without aura in adults. UBRELVY is not indicated for the preventive treatment of migraine.

Please see full Prescribing Information.

US-UBR-230117